Cilnidipine is an antihypertensive drug. It comes in a form of film-coated tablet and is available in three strengths, 5 mg, 10 mg and 20 mg.
It acts on the calcium channels of blood vessels and blocks the incoming calcium. This helps in suppressing the contraction of blood vessels, thereby reducing blood pressure. Cilnidipine dilates both arterioles and venules thus reducing the pressure.
The additional benefit of Cilacar is that it decreases blood pressure safely and effectively without excessive blood pressure reduction or tachycardia (an abnormally rapid heart rate).
It can also be used in elderly patients with diabetes and compromised renal function with chronic kidney disease.
Cilnidipine is launched in India by JB Chemicals & Pharmaceuticals Ltd. (JBCPL) in 2007. Established in 1976, JBCPL is one of India’s fastest growing pharmaceutical companies. It is an integrated, research-oriented organisation with a focus on supplying affordable, quality products both in India and International markets. JBCPL is trusted by healthcare professionals globally and operates in more than 30 countries across the world.